Antidiabetic and Antioxidant Effects of Acteoside from Jacaranda mimosifolia Family Biognoniaceae in Streptozotocin–Nicotinamide Induced Diabetes in Rats
| Autor: | Fatma A. Moharram, Siham M. El-Shenawy, Salma A. El-Marasy, Nagla A. El-Sherbeeny |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Antioxidant
medicine.medical_treatment lcsh:Medicine 030209 endocrinology & metabolism Type 2 diabetes Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus medicine 030212 general & internal medicine Pioglitazone business.industry lcsh:R Type 2 Diabetes Mellitus General Medicine Glutathione Acteoside medicine.disease Malondialdehyde Rats Antidiabetic chemistry Hemoglobin business medicine.drug |
| Zdroj: | Open Access Macedonian Journal of Medical Sciences; Vol. 8 No. A (2020): A-Basic Sciences; 125-133 Open Access Macedonian Journal of Medical Sciences, Vol 8, Iss A (2020) |
| ISSN: | 1857-9655 |
| DOI: | 10.3889/oamjms.2020.3325 |
| Popis: | BACKGROUND: Acteoside is a phenylethanoid compound isolated from Jacaranda mimosifolia D. Don leaves with a potential antidiabetic effect. OBJECTIVES: This study was designed to investigate the antidiabetic and antioxidant effects of acteoside in streptozotocin-nicotinamide (STZ-NA)-induced Type 2 diabetes in rats. METHODS: Diabetes was induced by intraperitoneal (i.p.) injection of a single dose of STZ (52.5 mg/kg), 15 min following i.p. administration of NA (25 mg/kg). Rats were divided into six groups; Group I: Normal rat group received the vehicle, Group II: Diabetic control group, and Groups III-IV: Diabetic rat groups were treated by either oral acteoside (10, 20, and 40 mg/kg) or pioglitazone (30 mg/kg) for 21 consecutive days. Biochemical parameters were assessed in the serum and liver homogenates. Examination of liver sections for histopathology was also carried out. RESULTS: Acteoside treated rats showed significant lower levels of blood glucose, glycosylated hemoglobin, total cholesterol, triglycerides, and increased serum insulin compared to control diabetic rats. Furthermore, acteoside treated rats, in comparison to the diabetic control, demonstrated significantly reduced malondialdehyde, increased reduced glutathione liver contents, and attenuated pathological alterations in the liver. These effects were comparable to those caused by the standard antidiabetic drug, pioglitazone. In vitro, acteoside scavenged stable free radical 1,1-diphenyl-2-picrylhydrazyl. CONCLUSION: Acteoside could be considered as a potential therapeutic agent for type 2 diabetes mellitus. However, studying further mechanisms underlying its antidiabetic effect is recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|